In a recent development, British pharmaceutical giant GSK has announced promising results from a late-stage study of its asthma drug, Nucala, in treating patients with chronic obstructive pulmonary disease (COPD), commonly referred to as 'smoker's lungs'. The study revealed that patients who received Nucala alongside an inhaled maintenance therapy for up to 104 weeks experienced a lower annualised rate of moderate or severe exacerbations compared to those who were given a placebo.
COPD, a condition characterized by restricted airflow and breathing difficulties, predominantly affects cigarette smokers in Western countries. With more than 300 million individuals worldwide affected by COPD, up to 40% of patients exhibit type 2 inflammation, marked by elevated levels of blood eosinophils.
Nucala, a monoclonal antibody that targets interleukin-5 to regulate eosinophils and reduce inflammation in the lungs, was initially approved in 2015 for severe asthma in the United States. With sales reaching 1.7 billion pounds in 2023, marking an 18% increase from the previous year, Nucala has become a significant contributor to GSK's revenue, accounting for nearly 6% of the company's total sales in 2023. This breakthrough study offers new hope for patients suffering from COPD and underscores the potential of Nucala as a treatment option for this debilitating respiratory condition.